share_log

Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

Nirvana Life Sciences Inc. 宣布任命谢尔顿·英文塔什为董事会成员
newsfile ·  2022/11/09 09:00

Vancouver, British Columbia--(Newsfile Corp. - November 9, 2022) - Nirvana Life Sciences Inc.(CSE: NIRV) (Nirvana or the "Company") , a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors.

不列颠哥伦比亚省温哥华--(Newsfile Corp.,2022年11月9日)——总部位于加拿大的生命科学公司(Nirvana或 “公司”),一家旨在开发非成瘾性慢性疼痛和复发预防产品的加拿大生命科学公司(CSE:NIRV)(Nirvana或 “公司”)很高兴地宣布任命谢尔登·英文塔什先生为公司董事会成员。

Mr. Inwentash is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of successful investing experience and an extensive track record of achieving significant ROI for his investors and profitability for the companies in which he invests. He founded ThreeD Capital to provide unique investment opportunities in several areas, specifically early stages of small cap stock, resource and disruptive technologies.

Inwentash先生是ThreeD Capital Inc.的创始人、董事长兼首席执行官。谢尔顿是一位资深的企业家,拥有超过30年的成功投资经验,在为投资者实现可观的投资回报率和所投资公司的盈利能力方面有着丰富的往绩。他创立了ThreeD Capital,旨在为多个领域提供独特的投资机会,特别是小盘股、资源和颠覆性技术的早期阶段。

Well-regarded in the investment industry, Sheldon has earned a reputation for creating significant shareholder value through early investments, having financed hundreds of public and private start-up companies, many of which went on to have successful exits.

谢尔顿在投资行业备受推崇,因通过早期投资创造可观的股东价值而赢得了声誉,他为数百家上市和私营初创公司提供了资金,其中许多公司后来成功退出。

Sheldon graduated from the University of Toronto with a B.Comm degree and, later, was awarded an honorary Doctor of Law degree from the university for his leadership as an entrepreneur, philanthropist and for his dedication to youth.

谢尔顿毕业于多伦多大学,获得商学学士学位,后来因其作为企业家、慈善家的领导能力和对青年的奉献精神而被该大学授予荣誉法学博士学位。

Mr. Inwentash commented, "I am very excited for the opportunity to join the board of Nirvana. As an early investor of the Company, I have seen the commitment and dedication of the Nirvana team to developing psychedelic formulations to treat addiction and manage pain. Nirvana's innovative approach to fighting the opioid crisis and other forms of addiction is revolutionary and positions the Company as a leader in the psychedelic healthcare industry". 

因温塔什先生评论说:“我很高兴有机会加入Nirvana的董事会。作为公司的早期投资者,我看到了Nirvana团队对开发迷幻配方以治疗成瘾和控制疼痛的承诺和奉献精神。Nirvana对抗阿片类药物危机和其他形式成瘾的创新方法具有革命性,使公司成为迷幻医疗行业的领导者”。

Mr. Bruce Clark, Chief Executive Officer of Nirvana commented, "We are pleased that Mr. Inwentash has chosen to join our Board, he brings a clear understanding of the value that alternative therapies can play in the treatment of addiction and management of chronic pain. His experience with disruptive technologies will be impactful as we move to the next phase of our development".

Nirvana首席执行官布鲁斯·克拉克先生评论说:“我们很高兴Inwentash先生选择加入我们的董事会,他清楚地了解了替代疗法在成瘾治疗和慢性疼痛管理方面可以发挥的价值。随着我们进入下一阶段的发展,他在颠覆性技术方面的经验将产生影响”。

For further information:
Bruce Clark- CEO
info@nirvanalifescience.com
Phone: 604-401-8100

欲了解更多信息:
布鲁斯·克拉克-首席执行官
info@nirvanalifescience.com
电话:604-401-8100

About Nirvana Life Sciences Inc.

关于 Nirvana Life Sciences Inc.

Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana's team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.

Nirvana Life Sciences Inc. 成立的目标很简单,就是研究和开发非成瘾性疼痛管理和复发预防产品,这些产品可以为患有慢性疼痛和/或与成瘾作斗争的患者提供更健康的疗效。Nirvana认为,在新型配方中使用天然来源的迷幻药有望提供有效控制疼痛和成瘾的非成瘾性解决方案。Nirvana的团队由来自全球的顶尖研究人员组成,将开发有可能使数百万人摆脱成瘾并每年为社会节省数十亿美元的疗法。

Forward Looking Statements

前瞻性陈述

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward- looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

本新闻稿包含加拿大证券法所指的某些前瞻性陈述和前瞻性信息(此处统称为 “前瞻性陈述”),包括但不限于有关公司未来投资的陈述。除历史事实陈述以外的所有陈述均为前瞻性陈述。不应过度依赖前瞻性陈述,前瞻性陈述本质上是不确定的,基于估计和假设,并且受已知和未知的风险和不确定性(一般和具体)的影响,这些风险和不确定性增加了前瞻性陈述所设想的未来事件或情况不发生的可能性。尽管公司认为本新闻稿中包含的前瞻性陈述中反映的预期以及做出此类前瞻性陈述所依据的假设是合理的,但无法保证此类预期会被证明是正确的。提醒读者不要过分依赖本文件中包含的前瞻性陈述,因为无法保证前瞻性陈述所依据的计划、意图或预期会发生。就其性质而言,前瞻性陈述涉及许多假设、已知和未知的风险和不确定性,这些风险和不确定性增加了预测、预测、预测和其他前瞻性陈述不发生的可能性,这可能导致公司的实际业绩和未来时期的业绩与此类前瞻性陈述所表达或暗示的对未来业绩或业绩的任何估计或预测存在重大差异。本新闻稿中包含的前瞻性陈述自发布之日起作出,除非适用法律要求,否则公司不承担任何公开更新或修改所包含的任何前瞻性陈述的义务。本警示声明明确限制了此处包含的前瞻性陈述。

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发